AdCLD-CoV19

AdCLD-CoV19
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Routes of; administration	Intramuscular
Identifiers
CAS Number	2698316-99-1;

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,^[2]^[3] a company from South Korea.^[4]

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.^[5] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.^[6] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.^[7] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.^[8]

References

^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
^ Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
^ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.
^ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
^ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
^ Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.
^ Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

Scholia has a profile for AdCLD-CoV19 (Q108415181).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

[1] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[2] Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.

[3] Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.

[4] "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.

[Trial_registration_NCT04666012-5] Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov

[Trial_registration_NCT05047692-6] Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[Preclinical_2022-7] Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.

[Registration_phase_2_trial_NCT05520970-8] Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]